Global ADHD Therapeutics Market Research Report- Forecast To 2024

Report / Search Code: MRFR/HC/1044-HCRR  Publish Date: December, 2018

Price

1-user PDF : $ 4450.0  Enterprise PDF : $ 6250.0

Description:

Global ADHD Therapeutics Information, by drug types (Stimulants and Non-stimulants), by distribution channels (hospitals, clinics, pharmacies, research laboratories and others) - Forecast to 2024

Market Synopsis of ADHD Therapeutics Market:

Market Scenario:

ADHD is one of the most common neurodevelopmental disorders of childhood. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive behaviors or be hyperactive. It is normal for children to have trouble focusing and behaving at one time or another. However, children with ADHD do not just grow out of these behaviors. The symptoms continue and can cause difficulty at school, at home, or with friends. A child with ADHD might daydream a lot, forget or lose things a lot, make careless mistakes, have difficulty getting along with others. Rising prevalence of ADHD and increasing awareness regarding ADHD are some of the factors responsible for the growth of the global ADHD therapeutics market. The market for ADHD therapeutics is growing rapidly. The global market for ADHD therapeutics is expected to reach US$ XX by the end of the forecasted period and is expected to grow at a CAGR of XX%

Study Objectives ADHD Therapeutics Market:

- To provide detailed analysis of the market structure along with forecast for the next 8 years of the various segments and sub-segments of the ADHD therapeutics market
- To provide insights about factors affecting the market growth
- To analyze the ADHD therapeutics market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
- To provide country level analysis of the market with respect to the current market size and future prospective
- To provide country level analysis of the market for segments by drug type, distribution channels and its sub-segments.
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global ADHD therapeutics market.

Key Players for ADHD Therapeutics Market:

Some of the key players in this market are: Concordia International Corp., Eli Lilly and Company, Highland Therapeutics Inc., Janssen Global Services LLC, NEOS Therapeutics Inc., Novartis AG, Noven Pharmaceuticals Inc., Pfizer Inc., Shire, Teva Pharmaceutical and others.

Segments:

Global ADHD therapeutics market has been segmented on the basis of drug types which comprises of stimulants and non-stimulants. On the basis of distribution channels, market is segmented into hospitals, clinics, pharmacies, research laboratories and others.

Regional Analysis of ADHD Therapeutics Market:

Globally North America is the largest market for ADHD therapeutics. The North American market for ADHD therapeutics is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Europe is the second-largest market for ADHD therapeutics which is expected to grow at a CAGR of XX%. Asia pacific region is expected to be growing in ADHD therapeutics market.

The report for Global ADHD therapeutics market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry.

Intended Audience

- ADHD drug manufacturers
- ADHD drug suppliers
- Research and Development (R&D) Companies
- Government Research Laboratories
- Independent Research Laboratories
- Government and Independent Regulatory Authorities
- Market Research and Consulting Service Providers
- Medical Research Laboratories
- Academic Medical Institutes and Universities

Contents:

1 INTRODUCTION
   1.1 DEFINITION
   1.2 SCOPE OF STUDY
   1.2.1 RESEARCH OBJECTIVE
   1.2.2 ASSUMPTIONS & LIMITATIONS
   1.2.2.1 ASSUMPTIONS
   1.2.2.2 LIMITATIONS
   1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
   2.1 RESEARCH PROCESS:
   2.2 PRIMARY RESEARCH
   2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
   3.1 DRIVERS
   3.2 RESTRAINTS
   3.3 OPPORTUNITIES
   3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
   4.1 PORTERS FIVE FORCES MODEL
4.2 Bargaining Power of Suppliers
4.3 Bargaining Power of Buyers
4.4 Threat of New Entrants
4.5 Threat of Substitutes
4.6 Intensity of Rivalry

5. Global ADHD Therapeutics Market, by Drug Type
5.1 Stimulants
5.1.1 Amphetamine
5.1.2 Methylenidate
5.1.3 Dextroamphetamine
5.1.4 Dextylenidate
5.1.5 Lisdexamfetamine
5.1.6 Other
5.2 Non-Stimulants
5.2.1 Atomoxetine
5.2.2 Bupropion
5.2.3 Guanfacine
5.2.4 Clonidine

6. Global ADHD Therapeutics Market, by Age Group
6.1 Pediatric and Adolescent
6.2 Adults

7. Global ADHD Therapeutics Market, by End Users
7.1 Specialty Clinics
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 Other

8. Global ADHD Therapeutics Market, by Region
8.1 Introduction
8.2 America
8.2.1 North America
8.2.1.1 US
8.2.1.2 Canada
8.2.2 South America
8.3 Europe
8.3.1 Western Europe
8.3.1.1 Germany
8.3.1.2 France
8.3.1.3 Italy
8.3.1.4 Spain
8.3.1.5 UK
8.3.1.6 Rest of Western Europe
8.3.2 Eastern Europe
8.4 Asia-Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 Republic of Korea
8.4.6 Rest of Asia-Pacific
8.5 Middle East & Africa
8.5.1 United Arab Emirates
8.5.2 Saudi Arabia
8.5.3 Oman
8.5.4 Kuwait
8.5.5 Qatar
8.5.6 Rest of Middle East & Africa

9. Competitive Landscape
9.1 Major Strategies Adopted by Market Players
9.1.1 Strategic Partnership
9.1.2 Merger & Acquisition

10. Company Profile
10.1 Amedra Pharmaceuticals LLC
10.1.1 Overview
10.1.2 Product Overview
10.1.3 Financials
10.1.4 Key Developments
10.2 Pfizer Inc
10.2.1 Overview
10.2.2 Product Overview
10.2.3 Financials
10.2.4 Key Developments
10.3 Glaxosmithkline
10.3.1 Overview
10.3.2 Product Overview
10.3.3 Financials
10.3.4 Key Development
10.4 Janssen Pharmaceuticals, Inc
10.4.1 Overview
10.4.2 Product Overview
10.4.3 Financials
10.4.4 Key Developments
10.5 NOVEN PHARMACEUTICALS, INC.
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS
10.6 CELLTECH GROUP LTD.
10.6.1 OVERVIEW
10.6.2 PRODUCT OVERVIEW
10.6.3 FINANCIALS
10.6.4 KEY DEVELOPMENTS
10.7 PURDUE PHARMA L.P.
10.7.1 OVERVIEW
10.7.2 PRODUCT OVERVIEW
10.7.3 FINANCIALS
10.7.4 KEY DEVELOPMENTS
10.8 PURDUE PHARMA L.P.
10.8.1 OVERVIEW
10.8.2 PRODUCT OVERVIEW
10.8.3 FINANCIALS
10.8.4 KEY DEVELOPMENTS
10.9 OTHERS
11 CONCLUSION
11.1 KEY FINDINGS
11.1.1 FROM CEO’S VIEWPOINT
11.1.2 UNMET NEEDS OF THE MARKET
11.2 KEY COMPANIES TO WATCH
11.3 PREDICTION OF PHARMACEUTICAL INDUSTRY
12 APPENDIX